Search | Clinical Trials Finder

Conditions: Epilepsy
Interventions: nasal Midazolam; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Sarcoma, Refractory Sarcoma
Interventions: Pazopanib, Irinotecan, Temozolomide; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 6 Years to 30 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Oakland, California • San Francisco, California • Boston, Massachusetts

Conditions: Stage III Intrahepatic Cholangiocarcinoma AJCC v7, Stage IIIA Gallbladder Cancer AJCC v7, Stage IIIB Gallbladder Cancer AJCC v7, Stage IVA Gallbladder Cancer AJCC v7, Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7, Stage IVB Gallbladder Cancer AJCC v7, Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7, Unresectable Extrahepatic Bile Duct Carcinoma, Unresectable Gallbladder Carcinoma
Interventions: Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Nab-paclitaxel; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 3
States / cities: Scottsdale, Arizona • Rochester, Minnesota • Houston, Texas

Conditions: Migraine
Interventions: ASY202, Placebo; Combination Product
Lead sponsor: Aspeya, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: Walnut Creek, California • Orlando, Florida • Las Vegas, Nevada + 2 more

Conditions: COVID-19
Interventions: ALG-097558, Dabigatran, Itraconazole, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Photoaging, Wrinkle, Skin Laxity
Interventions: Fractional Ablative CO2 Laser, Facial Cleanser, Facial Moisturizer, Sunscreen, Basic Ointment; Procedure · Other
Lead sponsor: Revision Skincare; Industry
Eligibility: 35 Years to 65 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Blue Ash, Ohio

Conditions: Vitiligo
Interventions: Rapamycin, Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 13 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Overweight, Obesity
Interventions: Formulation A (PF-07081532 20 mg plus 60 mg), Formulation B (PF-07081532 80 mg); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Influenza, Human
Interventions: FLU-Q-PAN H7N9 Formulation 1, FLU-Q-PAN H7N9 Formulation 2, FLU-Q-PAN H7N9 Formulation 3, AS03B, AS03A, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 833 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 8
States / cities: Stockbridge, Georgia • Meridian, Idaho • Cary, North Carolina + 5 more

Conditions: Herpes Zoster
Interventions: Herpes zoster vaccine GSK1437173A, Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 410 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 7
States / cities: Phoenix, Arizona • Pembroke Pines, Florida • Las Vegas, Nevada + 4 more

Conditions: Back Pain, Low
Interventions: Cannabidiol; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: B Cell Precursor Acute Lymphoblastic Leukemia
Interventions: Blinatumomab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 12 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 13
States / cities: Clovis, California • Duarte, California • Chicago, Illinois + 10 more

Conditions: Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage III Lung Cancer
Interventions: Biospecimen Collection, Carboplatin, Computed Tomography, Fludeoxyglucose F-18, Nab-paclitaxel, Pembrolizumab, Pemetrexed, Positron Emission Tomography, Radiation Therapy, [18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan, Ipilimumab, Nivolumab, Cemiplimab, Atezolizumab; Procedure · Drug · Other + 2 more
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Healthy
Interventions: LY3074828, LY3074828, Auto-injector (AI), Prefilled syringe (PFS); Biological · Drug · Device
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Constipation
Interventions: PEG3350; Drug
Lead sponsor: Braintree Laboratories; Industry
Eligibility: 4 Years to 16 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Little Rock, Arkansas • Morristown, New Jersey

Conditions: Glaucoma
Interventions: Latanoprost, Placebo, RO5093151; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Artesia, California • Aurora, Colorado • Morrow, Georgia + 3 more

Conditions: Healthy
Interventions: PF-05221304 Formulation A, PF-05221304 Formulation B; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Solid Tumor, Pancreatic Adenocarcinoma
Interventions: OBI-3424; Drug
Lead sponsor: OBI Pharma, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 5
States / cities: La Jolla, California • Los Angeles, California • New Brunswick, New Jersey + 2 more

Conditions: Schizophrenia and Related Disorders, Mitochondrial Alteration, Cognitive Impairment
Interventions: MitoQ, Placebo; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 35 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: New Haven, Connecticut • Belmont, Massachusetts

Conditions: Brain Tumor, Medulloblastoma, Brain Metastases
Interventions: WP1066; Drug
Lead sponsor: Emory University; Other
Eligibility: 3 Years to 25 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Pulmonary Arterial Hypertension
Interventions: Drug: RT234 - vardenafil inhalation powder; Device: Axially Oscillating Sphere dry powder inhaler (AOS DPI); Combination Product
Lead sponsor: Respira Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 26
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 22 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Danirixin HBr 50 mg IR Tablet, Danirixin FB 50 mg IR Tablet, Prilosec (omeprazole) 40mg Delayed-Release capsule; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 65 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Peanut Allergy, Peanut Hypersensitivity, Peanut-Induced Anaphylaxis, Immune System Diseases
Interventions: PVX-108, Placebo; Biological
Lead sponsor: Aravax Pty Ltd; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Little Rock, Arkansas • Rolling Hills Estates, California • Atlanta, Georgia + 5 more

Conditions: Healthy Volunteers
Interventions: Placebo, Maralixibat, Volixibat; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Knoxville, Tennessee

Search by objective public record fields.

Pharmacodynamics of Nasal and Buccal Midazolam Using EEG

PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma

Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers

Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients

Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers

Evaluating Procedure Pairing of a Post-Procedure Cream Versus a Comparator in Patients Treated With Fractional Ablative CO2 Laser for Facial Rejuvenation

Daily Topical Rapamycin for Vitiligo

A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years

Investigation of Cannabidiol for Reduction of NeuroInflammation in Chronic Back Pain

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

A Study of Two Formulations of LY3074828 in Healthy Participants

A Pilot Study of a New PEG3350 Dose Formulation For Use in Constipated Children

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).

OPEN LABEL, 2-PERIOD STUDY, TO COMPARE BIO-AVAILABILITY OF 2 DIFFERENT FORMULATIONS OF PF-05221304 IN HEALTHY ADULTS

A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors

MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction

WP1066 in Children With Refractory and Progressive or Recurrent Malignant Brain Tumors

Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study

A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Relative Bioavailability and Food Effect of Two Oral Formulations of GSK1325756 (Free Base vs HBr Salt) and Food Effect on the HBr Formulation When Given With Omeprazole

A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy

Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion